French researchers have identified 41 gene mutations in lung cancers associated with pulmonary fibrosis, a discovery that could lead to new therapy targets for both diseases. The findings applied to both non-idiopathic and idiopathic pulmonary fibrosis. Non-idiopathic cases are those that doctors have found a cause for, while Idiopathic cases…
The anti-inflammatory molecule protectin DX (PDX) has been shown to improve pulmonary fibrosis (PF) and lung function in mice, new research shows. The study, “Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice,” was published in the journal Scientific Reports. Lung fibrosis is characterized…
Esbriet (pirfenidone) can prolong idiopathic pulmonary fibrosis (IPF) patients’ survival, according to a review of clinical trials covering the anti-inflammatory and anti-fibrotic agent. Researchers also said that Esbriet is safe, but does not help every IPF patient. The study, “Role of pirfenidone in the management of pulmonary fibrosis,”…
Get regular updates to your inbox.
